trending Market Intelligence /marketintelligence/en/news-insights/trending/GzJKLM3_26F5klNPRVMnJw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Insys receives court approval for bankruptcy plan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Report: Insys receives court approval for bankruptcy plan

INSYS Therapeutics Inc. received U.S. court approval for its bankruptcy plan to sell the company and pay off creditors, The Wall Street Journal reported.

According to the report, the opioid drugmaker — the first to file for bankruptcy in the aftermath of the ongoing U.S. opioid crisis — will pay up to 8 cents on average for every dollar it owes. The plan was approved by U.S. Bankruptcy Judge Kevin Gross in Wilmington, Del., and will result in Insys' shareholders losing their investments. The settlement also prevents Insys' shareholders from suing those that guided the company into bankruptcy.

In June 2019, Chandler, Ariz.-based Insys filed for bankruptcy after it agreed to pay $225 million to settle investigations over unlawful marketing practices involving its opioid painkiller Subsys. Insys sold the rights to Subsys, as well as other assets, following the bankruptcy, but the sales are not enough to repay more than $1 billion the company owes to creditors.

The chapter 11 plan helps debtors reorganize a business to pay back creditors over time.

Insys pleaded guilty to allegations that it paid doctors kickbacks and used other fraudulent marketing practices to boost the sales of its highly addictive painkiller Subsys.

A number of companies, including Mallinckrodt PLC and Teva Pharmaceutical Industries Ltd., have reached settlements with states to resolve claims that certain marketing practices fueled the opioid epidemic, which kills about 200 Americans each day.